- Home
- JAZZ vs NUVL Comparison
JAZZ vs NUVL Comparison
Compare JAZZ & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- NUVL
- Stock Information
- Founded
- JAZZ 2003
- NUVL 2017
- Country
- JAZZ Ireland
- NUVL United States
- Employees
- JAZZ 2800
- NUVL N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- JAZZ Health Care
- NUVL Health Care
- Exchange
- JAZZ Nasdaq
- NUVL Nasdaq
- Market Cap
- JAZZ 7.0B
- NUVL 5.8B
- IPO Year
- JAZZ 2007
- NUVL 2021
- Fundamental
- Price
- JAZZ $108.94
- NUVL $76.98
- Analyst Decision
- JAZZ Strong Buy
- NUVL Strong Buy
- Analyst Count
- JAZZ 12
- NUVL 10
- Target Price
- JAZZ $183.00
- NUVL $119.60
- AVG Volume (30 Days)
- JAZZ 628.2K
- NUVL 484.7K
- Earning Date
- JAZZ 08-05-2025
- NUVL 08-11-2025
- Dividend Yield
- JAZZ N/A
- NUVL N/A
- EPS Growth
- JAZZ 49.21
- NUVL N/A
- EPS
- JAZZ 7.51
- NUVL N/A
- Revenue
- JAZZ $4,064,808,000.00
- NUVL N/A
- Revenue This Year
- JAZZ $6.10
- NUVL N/A
- Revenue Next Year
- JAZZ $5.07
- NUVL N/A
- P/E Ratio
- JAZZ $15.07
- NUVL N/A
- Revenue Growth
- JAZZ 5.76
- NUVL N/A
- 52 Week Low
- JAZZ $95.49
- NUVL $55.54
- 52 Week High
- JAZZ $148.06
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- JAZZ 48.58
- NUVL 46.00
- Support Level
- JAZZ $112.17
- NUVL $76.59
- Resistance Level
- JAZZ $117.39
- NUVL $83.50
- Average True Range (ATR)
- JAZZ 2.77
- NUVL 2.88
- MACD
- JAZZ -0.33
- NUVL -0.67
- Stochastic Oscillator
- JAZZ 24.15
- NUVL 22.91
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.